undamentalytics Newsletter
Sign in

Transmedics Group, Inc. income statement

In fiscal 2025, Transmedics Group, Inc. reported revenue of $605m, up 37.1% on the year before, operating income of $109m (a 17.9% margin) and net income of $190m, or $4.87 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1324263093242442605668
Cost of revenue710992888179243276
Gross profit614172165154262363392
Research and development142019222736566992
Selling, general and administrative1224243870120169185218
Operating income−20−30−26−39−31−293710982
Interest expense3444411141421
Income before tax−24−34−29−44−36−273610873
Income tax000—0−20−83−79
Net income−24−34−29−44−36−2535190152
Diluted EPS−$1.75−$2.36−$1.16−$1.60−$1.23−$0.77$1.01$4.87$3.83
Diluted shares (average)14m14m25m28m30m33m35m41m40m
EBITDA−19−28−25−38−28−2157136118

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: GKOS vs TMDXNVCR vs TMDXBVS vs TMDXATRC vs TMDX

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Transmedics Group, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Transmedics Group, Inc.